Cencora (COR) Projected to Announce Earnings on Wednesday

Cencora (NYSE:COR) will likely be issuing its Q4 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $4.58 per share and revenue of $87.95 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. During the same period last year, the business earned $4.00 EPS. The company’s quarterly revenue was up 5.1% on a year-over-year basis. On average, analysts expect Cencora to post $17.87 EPS for the current fiscal year and $19.77 EPS for the next fiscal year.

Cencora Price Performance

Shares of NYSE COR opened at $325.09 on Wednesday. Cencora has a one year low of $244.82 and a one year high of $377.54. The business’s 50-day moving average price is $322.60 and its two-hundred day moving average price is $317.67. The company has a market capitalization of $62.04 billion, a P/E ratio of 24.15 and a beta of 0.58.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, August 14th. Cencora’s dividend payout ratio (DPR) is 17.83%.

Wall Street Analyst Weigh In

Several research analysts recently commented on COR shares. Weiss Ratings upgraded shares of Cencora from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, October 6th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. increased their target price on Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Argus increased their target price on Cencora from $340.00 to $380.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Finally, Morgan Stanley raised their target price on Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $366.44.

Insider Buying and Selling at Cencora

In related news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.38% of the company’s stock.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.